Patents Examined by Ilia I Ouspenski
  • Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
    Patent number: 11072657
    Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 27, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Faith Nathan
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11066457
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: July 20, 2021
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • Intravesical therapy for bladder cancer
    Patent number: 11066478
    Abstract: This invention relates to an intravesical therapy for bladder cancer.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: July 20, 2021
    Assignee: PHOTOCURE ASA
    Inventor: Kjetil Hestdal
  • Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
    Patent number: 11046758
    Abstract: The present invention relates to combinations comprising anti-progastrin (anti-hPG) monoclonal antibodies and immune checkpoint inhibitors, as well as pharmaceutical compositions comprising said combinations. Methods of treatment of cancer using said combinations are also provided.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: June 29, 2021
    Assignee: PROGASTRINE ET CANCERS S.À R.L.
    Inventor: Alexandre Prieur
  • Humanized antibodies against c-Kit
    Patent number: 11041022
    Abstract: The invention provides antibodies specifically binding to c-Kit and methods of using such antibodies in stem cell replacement and treatment of cancer.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: June 22, 2021
    Assignee: FORTY SEVEN, INC.
    Inventors: Jie Liu, Kavitha Sompalli
  • Leukocyte infiltration promoting agent and antitumor immunostimulatory agent
    Patent number: 11033559
    Abstract: A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 15, 2021
    Assignee: OSAKA UNIVERSITY
    Inventors: Nobuyuki Takakura, Hisamichi Naito, Kazuhiro Takara
  • Inhibitors of T-cell activation
    Patent number: 11028170
    Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: June 8, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
  • Antigen binding proteins that bind PD-L1
    Patent number: 11027012
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 8, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
    Patent number: 11014987
    Abstract: The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutics NV
    Inventors: Linda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
  • Anti-VISTA antibodies and fragments
    Patent number: 11009509
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of detecting VISTA.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: May 18, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda A. Snyder, Gordon Powers, Manuel Alejandro Sepulveda, John D. Alvarez
  • ICOS critically regulates the expansion and function of inflammatory human Th17 cells
    Patent number: 11001805
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 11, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Immunostimulatory compositions, particles, and uses related thereto
    Patent number: 10987419
    Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: April 27, 2021
    Assignee: Emory University
    Inventor: Periasamy Selvaraj
  • Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
    Patent number: 10981992
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
    Patent number: 10981989
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: April 20, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
    Patent number: 10961309
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: March 30, 2021
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Isolated B7-H4 specific compositions and methods of use thereof
    Patent number: 10961288
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: March 30, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Agents and compositions for eliciting an immune response
    Patent number: 10953045
    Abstract: Immune-potentiating compositions include cells exhibiting enhanced antigen-presenting functions. The compositions are generally useful in facilitating the stimulation of host immune cell responses, including selective and targeted immune cell responses, and are particularly useful in the treatment and/or prophylaxis of cancers, tumors and pathogenic infections.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 23, 2021
    Assignee: CANCURE LIMITED
    Inventor: Stephen Ralph
  • Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
    Patent number: 10934336
    Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 2, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Xiaojun Liu, Wei Pan
  • Bi-specific antibodies against Tim-3 and PD-1 for immunotherapy in chronic immune conditions
    Patent number: 10934352
    Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: March 2, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Ana C. Anderson
  • VISTA antagonist and methods of use
    Patent number: 10933115
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 2, 2021
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S GOLLEGE LONDON
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle Lemercier, Elizabeth Nowak, Janet Lines, Li Wang, Mark Spaller